Matches in Wikidata for { <http://www.wikidata.org/entity/Q65535905> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q65535905 description "clinical trial" @default.
- Q65535905 description "ensayu clínicu" @default.
- Q65535905 description "klinisch onderzoek" @default.
- Q65535905 description "клінічне випробування" @default.
- Q65535905 name "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery" @default.
- Q65535905 name "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery" @default.
- Q65535905 type Item @default.
- Q65535905 label "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery" @default.
- Q65535905 label "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery" @default.
- Q65535905 prefLabel "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery" @default.
- Q65535905 prefLabel "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery" @default.
- Q65535905 P1050 Q65535905-7E61B3E9-86B1-43B8-AC05-D2DFD39FAB28 @default.
- Q65535905 P1132 Q65535905-4AE6B533-465F-4370-961A-AC2E7C38CF95 @default.
- Q65535905 P1476 Q65535905-E6CC4710-EE07-4E3B-AFB4-81963592CCA6 @default.
- Q65535905 P17 Q65535905-2BDA1ED6-DAF3-48F0-9762-94CD217F5308 @default.
- Q65535905 P17 Q65535905-D02BC9B4-B067-45BE-A434-79B9A45AF410 @default.
- Q65535905 P2899 Q65535905-082361DB-1D40-4566-B68E-B3E5877FB4F4 @default.
- Q65535905 P3098 Q65535905-9910A8AF-7770-4DBF-AF9F-45D3238A4CFF @default.
- Q65535905 P31 Q65535905-FF17F771-7A25-424D-9D5A-3ED62F875231 @default.
- Q65535905 P580 Q65535905-7F0A297B-7C1A-44CD-AD62-35BBFC50B709 @default.
- Q65535905 P582 Q65535905-4D688EFD-5575-493F-9CD8-FF9A3909496C @default.
- Q65535905 P6099 Q65535905-D6C93056-B03A-4386-A0A1-0CD156EBF23B @default.
- Q65535905 P6153 Q65535905-9B9B9AF5-305E-4442-BD71-F085353450CD @default.
- Q65535905 P6153 Q65535905-A60F4374-6536-42E4-B0FC-CA5EF33F0413 @default.
- Q65535905 P8363 Q65535905-9A5651B2-7E0B-4187-82CE-1A990085E7C0 @default.
- Q65535905 P1050 Q33525 @default.
- Q65535905 P1132 "+16" @default.
- Q65535905 P1476 "Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma" @default.
- Q65535905 P17 Q30 @default.
- Q65535905 P17 Q55 @default.
- Q65535905 P2899 "+18" @default.
- Q65535905 P3098 "NCT01061411" @default.
- Q65535905 P31 Q30612 @default.
- Q65535905 P580 "2010-02-06T00:00:00Z" @default.
- Q65535905 P582 "2015-10-14T00:00:00Z" @default.
- Q65535905 P6099 Q5452194 @default.
- Q65535905 P6153 Q1065414 @default.
- Q65535905 P6153 Q7370121 @default.
- Q65535905 P8363 Q78089383 @default.